Pan-ELR+ CXC chemokine antibodies
US9783605B2 · kind B2 · utility
3Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2016 |
| Grant date | Oct 10, 2017 |
| Priority date | — |
| Expiry date | Feb 3, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.